AuthorisedTherapeutic confirmatory (Phase III)Interventional

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

This research study is looking into a new treatment for a specific type of cancer called nasopharyngeal cancer. This is for patients whose cancer has either returned after previous treatment or has spread to other parts of the body. The treatment combines a drug called toripalimab with standard chemotherapy. This study is mainly focused on people living in areas where nasopharyngeal cancer isn't usually common. Doctors want to find out how safe this new treatment combination is and how well it works to control the cancer. They will be carefully watching for any side effects and how long patients live and how long their cancer stays under control.

At a glance

Status

Authorised

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Humanitas Mirasole S.p.A.

Enrolment target

Start

13 Oct 2025

Recurrent Metastatic Nasopharingeal Carcinoma

What is this study about?

This study is a Phase III clinical trial, which means it's a key stage of research before a new treatment might become widely available. Doctors are investigating a new way to treat nasopharyngeal cancer that has either reappeared (recurrent) or spread to other parts of the body (metastatic). This type of cancer affects the upper part of the throat behind the nose.

The main idea is to combine a newer drug, toripalimab, with standard chemotherapy. Toripalimab is a type of immunotherapy, which helps your body's own immune system fight cancer. Chemotherapy uses strong medicines to kill cancer cells. The aim is to see if this combination improves how well patients do compared to existing treatments, and to understand any side effects.

It's important to study this treatment in people from places where nasopharyngeal cancer is not as common, as the disease might behave differently in various populations. By doing this, researchers hope to find a more effective and safe treatment option for a wider group of patients with this challenging form of cancer.

Key takeaways

This study tests a new treatment for nasopharyngeal cancer that has returned or spread.
It combines an immunotherapy drug (toripalimab) with standard chemotherapy.
The main goals are to check the treatment's safety and how well it controls the cancer.
It's a Phase III study, a key step before potential widespread use.
Participants must be 18 or older with recurrent or metastatic nasopharyngeal cancer.
Close monitoring for side effects and cancer progression will occur.

Who may be eligible?

To be able to join this study, you must be at least 18 years old. There is no upper age limit, meaning older adults can also take part. The study is open to both men and women.

Generally, you would be considered if you have nasopharyngeal cancer that has either come back after past treatment or has spread to other parts of your body. Doctors will also check your general health and make sure you meet other specific medical requirements to ensure the treatment is suitable and safe for you.

It's important to discuss your full medical history with the study team. They will have detailed criteria to determine if this study is the right option for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have nasopharyngeal cancer?
Has your nasopharyngeal cancer come back or spread?
Are you able to travel to study appointments?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will receive a combination of medicines: toripalimab and chemotherapy. These drugs are usually given through a drip (infusion) into your vein. The specific schedule and number of treatments will be explained by the study team.

You will have regular visits to the clinic for blood tests, physical examinations, and scans (like X-rays or CT scans) to see how you are responding to the treatment and to monitor for any side effects. The doctors and nurses will ask you detailed questions about how you are feeling. These visits are important for your safety and to gather necessary information for the study.

The total duration of your participation will depend on how you respond to the treatment and the study plan. Even after completing the main treatment, you will likely have follow-up appointments for a period to track your long-term health. You can always ask the study team for a detailed schedule of visits and treatments.

Potential risks and benefits

Taking part in this study might offer potential benefits, such as access to a new treatment approach that could be more effective than standard care, and your health will be closely monitored. However, like all medical treatments, there are potential risks, primarily side effects from the medications. The study is specifically looking at serious side effects. The medical team will carefully explain all known risks and manage any side effects that occur. You have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Italy

Common questions

What is nasopharyngeal cancer?

It's a type of cancer that starts in the upper part of your throat, behind your nose.

What does 'recurrent and/or metastatic' mean?

It means the cancer has come back after treatment, or it has spread from where it started to other parts of your body.

What is toripalimab?

Toripalimab is a type of immunotherapy drug designed to help your body's immune system fight cancer cells.

What does 'first-line treatment' mean?

This means it's the first treatment given for this stage of your cancer, not a treatment used after others have failed.

What will doctors be checking in this study?

They will be checking for side effects, how long the cancer stays under control, and how long people live.